Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LEU011 in Relapsed/Refractory Solid Tumours
NCT06193902Phase 2Recruiting
- Sponsor
- Leucid Bio
- Start
- Nov 2023
- Primary completion
- May 2029
- Modality
- Gene Editing, Gene Silencing, Autologous CAR-T
- Countries
- 1
01
Overview
A Phase 2 trial of LEU011 in solid tumor, sponsored by Leucid Bio. Started Nov 2023; status: recruiting.
02
Drugs
LEU011
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06193902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193902.